跳至主要内容
临床试验/ACTRN12612000796886
ACTRN12612000796886尚未招募不适用

For healthy human volunteers, what is the dose-dependent independent and combined impact of alcohol and energy drinks on cognitive and motor performance, physiology, and behavioural risk-taking outcomes

School of Psychology, University of Tasmania0 个研究点目标入组 46 人开始时间: 2012年7月30日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Educational / counselling / training
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 35 Years(—)
性别
All

入选标准

  • Male or female
  • Aged 18 to 35
  • English as a first language
  • Completed Year 12 or equivalent
  • Current full driver licence
  • Regular energy drink consumer (minimum consumption of one energy drink and maximum consumption of one energy drink per day on average in the preceding month)
  • Regular caffeine consumer (minimum consumption of five and maximum consumption of 28 caffeinated products in the preceding week)
  • Regular alcohol consumer (minimum consumption of two standard alcoholic beverages in the preceding fortnight)
  • Normal or corrected-to-normal vision
  • Normal sleep patterns
  • Normal Body Mass Index (BMI; between 18.50 and 29.99)
  • Provided informed consent

排除标准

  • Regular tobacco smoker (typical daily use of one or more cigarettes)
  • Recent illicit drug use (preceding two weeks)
  • Current regular medicinal or recreational prescription medication use (excluding the contraceptive pill)
  • Participation in a drug study in the preceding three months
  • Currently pregnant or breastfeeding
  • History of any significant neurological condition
  • Current diagnosis of any significant physical condition
  • Current diagnosis of a significant psychiatric disorder or score of 30 or higher on the Kessler Psychological Distress Scale (K10; Kessler et al., 2002)
  • Current diagnosis of a significant intellectual disability or age normed quotient lower than 71 on the Wechsler Test of Adult Reading (WTAR; Wechsler, 2001)
  • History of alcohol or drug abuse or dependence disorder or use of alcohol at hazardous or harmful levels, evident via a score of 16 or higher on the Alcohol Use Disorders Identification Test (AUDIT; Barbor et al., 2001; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993)

研究者

发起方
School of Psychology, University of Tasmania

相似试验

进行中(未招募)
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years
EUCTR2011-001292-39-DEInstitut de Recherches Internationales Servier90
进行中(未招募)
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years
EUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
进行中(未招募)
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disorders
EUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
进行中(未招募)
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disorders
EUCTR2011-001292-39-ESab Servier116
进行中(未招募)
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years.Paediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 16.0 Level: LLT Classification code 10008908 Term: Chronic heart failure System Organ Class: 100000004849
EUCTR2011-001292-39-GBInstitut de Recherches Internationales Servier116
A crossover, single-blind, placebo-controlled study... | 临床试验